Clinigen Group PLC (CLIN) Given “Buy” Rating at Peel Hunt
Peel Hunt reissued their buy rating on shares of Clinigen Group PLC (LON:CLIN) in a research note issued to investors on Tuesday. The firm currently has a GBX 1,000 ($12.19) target price on the stock.
Several other research firms have also issued reports on CLIN. N+1 Singer reissued a buy rating and set a GBX 800 ($9.75) target price on shares of Clinigen Group PLC in a research note on Wednesday, September 28th. Numis Securities Ltd reissued a buy rating and set a GBX 933 ($11.37) target price on shares of Clinigen Group PLC in a research note on Wednesday, September 28th. Finally, Stifel Nicolaus reissued a buy rating and set a GBX 800 ($9.75) target price on shares of Clinigen Group PLC in a research note on Wednesday, September 28th. Five analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and a consensus target price of GBX 856.60 ($10.44).
Shares of Clinigen Group PLC (LON:CLIN) opened at 772.50 on Tuesday. The stock’s market cap is GBX 885.28 million. The company has a 50-day moving average price of GBX 695.99 and a 200-day moving average price of GBX 612.87. Clinigen Group PLC has a 12 month low of GBX 492.75 and a 12 month high of GBX 793.50.
The firm also recently announced a dividend, which will be paid on Friday, November 25th. Stockholders of record on Thursday, November 3rd will be given a dividend of GBX 2.70 ($0.03) per share. This represents a dividend yield of 0.38%. The ex-dividend date of this dividend is Thursday, November 3rd. This is a positive change from Clinigen Group PLC’s previous dividend of $1.30.
In other news, insider Shaun Edward Chilton sold 97,246 shares of the firm’s stock in a transaction dated Tuesday, October 18th. The stock was sold at an average price of GBX 750 ($9.14), for a total transaction of £729,345 ($888,903.11).
About Clinigen Group PLC
Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP).
Receive News & Stock Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related stocks with our FREE daily email newsletter.